|
|
- 2017
SAHA对胃癌MGC-803细胞增殖与周期及凋亡的影响
|
Abstract:
摘要：目的 研究组蛋白去乙酰化酶抑制剂(SAHA)对胃癌细胞株MGC-803增殖、凋亡及周期的影响。方法 MTT比色法观察不同药物浓度SAHA作用于培养胃癌细胞株MGC-803时的增殖变化，初步选取药物作用48h时的合适药物浓度，进一步用流式细胞术检测1、2μmol/L SAHA对MGC-803细胞凋亡及周期的影响，Western blot检测乙酰化组蛋白3、4及cyclin D1蛋白的表达情况。结果 与正常对照组相比，SAHA处理组细胞增殖能力降低，凋亡率升高，细胞周期内G1期比率升高，差异均具有统计学意义(P<0.05)；Western blot检测结果显示，与正常对照组相比，SAHA处理组的乙酰化组蛋白3、乙酰化组蛋白4升高，而cyclin D1含量降低，差异均具有统计学意义(P<0.01)。结论 组蛋白去乙酰化酶抑制剂SAHA可以抑制MGC-803细胞增殖，通过G1-S期阻滞抑制细胞周期，促进细胞凋亡，可能与促进乙酰化组蛋白3及乙酰化组蛋白4的表达增多有关。
ABSTRACT: Objective To study the effects of histone deacetylase inhibitor SAHA on the proliferation, apoptosis and cycle of gastric cancer cell MGC-803. Methods The gastric cancer cell line MGC-803 was treated with SAHA, and then appropriate drug concentrations were selected by MTT assay. The cell apoptosis and cycle were analyzed by flow cytometry. After treatment with SAHA 1μmol/L and SAHA 2μmol/L, the expression levels of acetylated histone H3, acetylated histone H4 and cyclin D1 proteins were evaluated by Western blot. Results Compared with those in the normal control group, the group treated with SAHA inhibited cell proliferation, increased apoptosis rate, increased G1 phase ratio, all with significant differences (P<0.05). In the group treated with SAHA, the expressions of Ac-H3 and Ac-H4 increased, but the expression of cyclin D1 decreased, all with significant differences (P<0.01). Conclusion Histone deacetylase inhibitor SAHA inhibits the proliferation of MGC-803 cell and promotes G1/S phase cell cycle arrest followed by apoptosis, which might be induced by the increased expressions of Ac-H3 and Ac-H4
| [1] | 艾林，龙娟，王楠，等. 抗肿瘤药物新靶点：组蛋白去乙酰酶的研究进展[J]. 药学学报, 2005, 40(7):585-590. |
| [2] | ABAZA MS, BAHMAN AM, AL-ATTIYAH RJ, et al. Synergistic induction of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome inhibitors: potential mechanisms of action[J]. Tumour Biol, 2012, 33(6):1951-1972. |
| [3] | BAI LY, OMAR HA, CHIU CF, et al. Antitumor effects of (S)-HDAC42,a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells[J]. Cancer Chemother Pharmacol, 2011, 68(2):489-496. |
| [4] | 庄涵虚. RNA干扰沉默胃癌HDAC1基因表达的实验研究[D]. 福建：福建医科大学, 2011. |
| [5] | SHI Y, SHARMAA, WU H, et al. Cyclin D1 and c-myc internal ribosome entry site (IRES)-dependent translation is regulated by AKT activity and enhanced by rapamycin through a p38 MAPK- and ERK-dependent pathway[J]. J Biol Chem, 2005, 280(12):10964-10973. |
| [6] | GOZZINI A, ROVIDA E, DELLO SBARBA P, et al.Butyrates, as a single drug, induce histone acetylation and granulocytic maturation:possible selectivity on core binding factor-acute myeloid leukemia blasts[J]. Cancer Res, 2003, 63(24):8955-8961. |
| [7] | DEBES JD, SEBO TJ, LOHSE CM, et al. p300 in prostate cancer proliferation and progression[J]. Cancer Res, 2003, 63(22):7638-7640. |
| [8] | GAYTHER SA, BATLEY SJ, LINGER L, et al. Mutations truncating the EP300 deacetylase in human cancers[J]. Nat Genet, 2000, 24(3):300-303. |
| [9] | KHAN O, LA THANGUE NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications[J]. Immunol Cell Biol, 2012, 90:85-94. |
| [10] | KUBO M, KANAYA N, PETROSSIAN K, et al. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)[J]. Breast Cancer Res Treat, 2013, 137(1):93-107. |
| [11] | TORRES-PADILLA ME, PARFITT DE, KOUZARIDES T, et al. Histone arginine methylation regulates pluripotency in the early mouse[J]. Embryo Nature, 2007, 445 (7124):214-218. |
| [12] | PFLUM MK, TONG JK, LANE WS, et al. Histone deacetylase 1 phosphorylation promotes enzymatic activity and complex formation[J]. J Biol Chem, 2001, 276(50):47733-47741. |
| [13] | MUSGROVE EA, CALDON CE, BARRACLOUGH J, et al. Cyclin D as a therapeutic target in cancer[J]. Nat Rev Cancer, 2011, 11(8):558-572. |
| [14] | JIANG GM, WANG HS, ZHANG F, et al. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of snail facilitates cancer progression[J]. Biochim Biophys Acta, 2013, 1833(3):663-671. |
| [15] | 聂建云，刘馨，金从国，等. 组蛋白去乙酰化酶抑制剂对乳腺癌细胞株MCF-7增殖周期的影响[J]. 中国综合临床, 2009, 25(12):1238-1240. |
| [16] | LEE YJ, WON AJ, LEE J, et al. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells[J]. Int J Med Sci, 2012, 9(10):881-893. |
| [17] | NOH EJ, LEE JS. Functional interplay between modulation of histone deacetylase activity and its regulatory role in G2/M transition[J]. Biochem Biophys Res Commun, 2003, 310(2):267-273. |
| [18] | LIN YY, QI Y, LU JY, et al. A comprehensive synthetic genetic interaction network governing yeast histone aeetylation and deacetylation[J]. Genes Dev, 2008, 22(15):2062-2074. |
| [19] | 邹琛，周俊，陆国平. 组蛋白去乙酰化酶抑制剂与细胞周期和凋亡关系的研究进展[J].中国病理生理杂志, 2007, 23(12):2487-2490. |
| [20] | BATTA K, DAS C, GADAD S, et al. Reversible acetylation of non histone proteins: role in cellular function and disease[J]. Subcell Biochem, 2007, (41):193-212. |
| [21] | 白娟，刘继彦，郑玲. 组蛋白去乙酰化酶抑制抗肿瘤的研究进展[J]. 现代肿瘤医学, 2009, 17(6):1194-1196. |
| [22] | ESTELLER M. Cancer epigenomics: DNA methylomes and histone-modification maps[J]. Nat Rev Genet, 2007, 8(4):286-298. |
| [23] | 韩艳，张美花，金铁峰，等. HDAC1和HDAC6蛋白过表达在卵巢浆液性癌中的临床病理学意义[J]. 临床与实验病理学杂志, 2010, 26(4):394-396. |
| [24] | 林朗，郑元回，林克荣. 胃癌组织中Survivin、CerbB-2和p53的表达及其临床意义[J]. 中化消化杂志, 2011, 31(8):562-563. |
| [25] | KAWAMATA N, CHEN J, KOEFFLER HP. Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells[J]. Blood, 2007, 110(7):2667-2673. |
